$0.41
(5.37%)
Add to watchlist
Create an alert
Stocks and Shares ISACervoMed Inc. is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that cause disease in Lewy bodies (DLB) and certain other neurological disorders. It focuses on reducing the impact of inflammation in the brain, or neuroinflammation, which is a key factor in the manifestation of degenerative diseases of the brain, including DLB. Neflamapimod is being evaluated in the Company's ongoing RewinD-LB Trial, a Phase 2b trial in patients with DLB.
Company Information
About this company
Key people
John J. Alam
President, Chief Executive Officer, Director
William R. Elder
Chief Financial Officer, General Counsel, Corporate Secretary
Kelly Blackburn
Executive Vice President - Clinical Development
Mark De Rosch
Executive Vice President - Regulatory and Government Affairs and Program Management
Marco Verwijs
Executive Vice President - Technical Operations
Claudia Ordonez
Senior Vice President - Medical Science
Joshua S. Boger
Independent Chairman of the Board
Robert J. Cobuzzi
Director
Sylvie L. Gregoire
Director
David Quigley
Director
Jane H. Hollingsworth
Independent Director
Click to see more
Key facts
- Shares in issue9.25m
- EPICCRVO
- ISINUS15713L1098
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$72.26m
- Employees15
- ExchangeNASDAQ
- Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.